人促红素注射液与罗沙司他联合铁剂治疗肾性贫血的疗效及安全性  

Efficacy and safety of human erythropoietin injection and Roxadustat combined with iron in the treatment of renal anemia

作　　者：侯西倩 Hou Xiqian(Department of Nephrology,Zoucheng People s Hospital,Zoucheng Shandong,273500,China)

机构地区：[1]邹城市人民医院肾内科,山东邹城273500

出　　处：《中外女性健康研究》2025年第3期30-32,180,共4页Women's Health Research

摘　　要：目的:探讨人促红素注射液与罗沙司他联合铁剂治疗肾性贫血的疗效及安全性。方法:选取2022年8月至2024年8月本院收治的肾性贫血患者60例,采用随机数字表法分为对照组(n=30)和观察组(n=30)。对照组采取人促红素注射液联合铁剂治疗,观察组采取人促红素注射液+罗沙司他联合铁剂治疗。比较两组的临床效果、血常规指标、铁代谢指标及用药安全性。结果:观察组治疗有效率93.33%明显高于对照组的70.00%(P<0.05)。治疗后,两组的Hct、RBC、MCV较治疗前明显升高,CRP较治疗前明显下降(P<0.05),且观察组Hct、RBC、MCV高于对照组,CRP低于对照组(P<0.05)。治疗后,两组的Hb、TSAT、SF、TIBC、SI较治疗前明显升高(P<0.05),且观察组Hb、TSAT、SF、TIBC、SI高于对照组(P<0.05)。观察组不良反应发生率30.00%与对照组的13.33%比较,差异无统计学意义(P>0.05)。结论:人促红素注射液+罗沙司他联合铁剂治疗肾性贫血可有效提升临床效果,纠正贫血症状,提升红细胞、血红蛋白含量,减轻铁代谢紊乱,且安全性佳。Objective:To investigate the efficacy and safety of human erythropoietin injection and Roxadustat combined with iron in the treatment of renal anemia.Methods:Sixty patients with renal anemia admitted to our hospital from August 2022 to August 2024 were selected and divided into control group(n=30)and observation group(n=30)by random number table method.The control group was treated with human erythropoietin injection combined with iron,and the observation group was treated with human erythropoietin injection combined with Roxadustat.The clinical effects,blood routine indexes,iron metabolism indexes and drug safety of the two groups were compared.Results:The effective rate of the observation group was 93.33%higher than that of the control group 70.00%(P<0.05).After treatment,Hct,RBC and MCV in both groups were significantly higher than before treatment,while CRP was significantly lower than before treatment(P<0.05),and Hct,RBC and MCV in observation group were higher than those in control group,while CRP was lower than those in control group(P<0.05).After treatment,Hb,TSAT,SF,TIBC and SI in both groups were significantly higher than before treatment(P<0.05),and Hb,TSAT,SF,TIBC and SI in observation group were higher than those in control group(P<0.05).The incidence of adverse reactions in the observation group was 30.00%compared with 13.33%in the control group,and there was no significant difference(P>0.05).Conclusion:Human erythropoietin injection+Roxadustat combined with iron agent can effectively improve the clinical effect,correct the symptoms of anemia,increase the content of red blood cells and hemoglobin,and reduce the disorder of iron metabolism,with good safety.

关 键 词：肾性贫血 人促红素注射液 罗沙司他 铁剂 

分 类 号：R556[医药卫生—血液循环系统疾病]